Chinese Expert Consensus on the Combination of Targeted Therapy and Immunotherapy with Locoregional Therapy for Intermediate/Advanced Hepatocellular Carcinoma
Xinyu Bi,Yinying Lu,Bo Chen,Zhengqiang Yang,Zhixian Hong,Hanping Wang,Yongkun Sun,Xiaodong Wang,Chunwang Yuan,Daobing Zeng,Zhen Huang,Aiping Zhou,Wen Zhang,Shunda Du,Jianjun Zhao,Jianguo Zhou,Yirui Zhai,Xu Che,Hong Zhao,Haitao Zhao,Jianqiang Cai
DOI: https://doi.org/10.1159/000540857
2024-01-01
Liver Cancer
Abstract:Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality, it ranks as the second most common cause of cancer deaths in China. Most HCC patients are first diagnosed at an advanced stage. In recent years, targeted therapy combined with immunotherapy has become the preferred regimen for systemic treatment of intermediate-advanced HCC, while targeted therapy combined with immunotherapy plus local treatment could further improve the efficacy in many clinical studies. To better guide the clinical treatment for effective and safe combination therapy, our interdisciplinary panel on the treatment of intermediate-advanced HCC comprising hepatologists, hepatobiliary surgeons, oncologists, radiologists, interventional radiologists and traditional Chinese medicine physicians have formulated this consensus based on current clinical studies and clinical medication experience for reference. The consensus contained 15 recommendations, including the applicable population and management, local treatment selection, conversion strategy, treatment strategy after tumor progression and management of common adverse reactions.